Movatterモバイル変換

[0]ホーム
URL:

PE20050965A1 - Procedimiento para la preparacion de compuestos de aminocrotonilo - Google Patents

Procedimiento para la preparacion de compuestos de aminocrotonilo

Info

Publication number
PE20050965A1
PE20050965A1PE2004001000APE2004001000APE20050965A1PE 20050965 A1PE20050965 A1PE 20050965A1PE 2004001000 APE2004001000 APE 2004001000APE 2004001000 APE2004001000 APE 2004001000APE 20050965 A1PE20050965 A1PE 20050965A1
Authority
PE
Peru
Prior art keywords
compound
tetrahidrofuran
iloxi
amino
quinazoline
Prior art date
Application number
PE2004001000A
Other languages
English (en)
Inventor
Rainer Soyka
Werner Rall
Juergen Schnaubelt
Peter Sieger
Christian Kulinna
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filedlitigationCriticalhttps://patents.darts-ip.com/?family=34428508&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20050965(A1)"Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim IntfiledCriticalBoehringer Ingelheim Int
Publication of PE20050965A1publicationCriticalpatent/PE20050965A1/es

Links

Classifications

Landscapes

Abstract

SE REIFERE A UN PROCEDIMIENTO PARA LA PREPARACION DE COMPUESTOS DE AMINOCROTONILO EN ESPECIAL DEL COMPUESTO 4-[(3-CLORO-4-FLUOROFENIL)AMINO]-6-{[4-(N,N-DIMETILAMINO)-1-OXO-2-BUTEN-1-IL]AMINO}-7-((S)-TETRAHIDROFURAN-3-ILOXI)-QUINAZOLINA, QUE COMPRENDE LAS SIGUIENTES ETAPAS: a) REACCION DEL COMPUESTO AMINOARILO DE FORMULA (V), PREFERENTEMENTE N4-(3-CLORO-4-FLUORO-FENIL)-7-(TETRAHIDROFURAN-3-ILOXI)-QUINAZOLIN-4,6-DIAMINA EN DISOLVENTES ADECUADOS, DESPUES DE LA CORRESPONDIENTE ACTIVACION CON ACIDO DI-(ALQUIL(C1-C4))-FOSFONOACETICO; b) LA REACCION DE LA ARILAMINA DE FORMULA (VI) OBTENIDA, TAL COMO ESTER DIALQUILICO DE ACIDO {[4-(3-CLORO-4-FLUORO-FENIL)AMINO-7-((S)-TETRAHIDROFURAN-3-ILOXI)-QUINAZOLIN-6-ILCARBAMOIL]-METIL}-FODFONICO, CON EL ALDEHIDO PREPARADO IN SITU A PARTIR DEL CORRESPONDIENTE (DIMETILAMINO)-ACETALDEHIDO-DIALQUILACETAL, CON EMPLEO DE BASES ORGANICAS E INORGANICAS ADECUADAS, TALES COMO LA BASE DBU (1,5-DIAZABICICLO[4.3.0]NON-5-ENO, HIDROXIDO DE SODIO O POTASIO, Y c) LA TRANSFORMACION DEL COMPUESTO EN SU SAL DE DIMALEATO, POR RECCION BAJO CALENTAMIENTO CON ACIDO MANDELICO EN UN DISOLVENTE ADECUADO. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE CONTIENE EL COMPUESTO EN FORMA DE SAL DIMALEATO, EL CUAL ES ADECUADO PARA EL TRATAMIENTO DE TUMORES, ENFERMEDADES DE LAS VIAS RESPIRATORIAS Y GASTROINTESTINALES
PE2004001000A2003-10-172004-10-15Procedimiento para la preparacion de compuestos de aminocrotoniloPE20050965A1 (es)

Applications Claiming Priority (1)

Application NumberPriority DateFiling DateTitle
DE10349113ADE10349113A1 (de)2003-10-172003-10-17Verfahren zur Herstellung von Aminocrotonylverbindungen

Publications (1)

Publication NumberPublication Date
PE20050965A1true PE20050965A1 (es)2005-12-19

Family

ID=34428508

Family Applications (2)

Application NumberTitlePriority DateFiling Date
PE2004001000APE20050965A1 (es)2003-10-172004-10-15Procedimiento para la preparacion de compuestos de aminocrotonilo
PE2010000135APE20100267A1 (es)2003-10-172004-10-15Procedimiento para la preparacion de compuestos de aminocrotonilo

Family Applications After (1)

Application NumberTitlePriority DateFiling Date
PE2010000135APE20100267A1 (es)2003-10-172004-10-15Procedimiento para la preparacion de compuestos de aminocrotonilo

Country Status (35)

CountryLink
US (2)US20050085495A1 (es)
EP (2)EP2508521B2 (es)
JP (2)JP4594317B2 (es)
KR (2)KR101180752B1 (es)
CN (2)CN101402631A (es)
AR (1)AR046118A1 (es)
AU (2)AU2004281938B2 (es)
BR (2)BR122013033343B8 (es)
CA (2)CA2759063C (es)
CY (2)CY1114866T1 (es)
DE (1)DE10349113A1 (es)
DK (2)DK2508521T4 (es)
EA (1)EA016624B1 (es)
EC (1)ECSP066509A (es)
ES (2)ES2440466T3 (es)
HK (1)HK1095817A1 (es)
HR (2)HRP20160246T4 (es)
HU (1)HUE028254T2 (es)
IL (2)IL174951A (es)
ME (1)ME00341B (es)
MX (2)MX338920B (es)
MY (2)MY155425A (es)
NO (2)NO333971B1 (es)
NZ (2)NZ583049A (es)
PE (2)PE20050965A1 (es)
PL (2)PL1678165T3 (es)
PT (2)PT2508521E (es)
RS (3)RS60563B1 (es)
SG (1)SG139743A1 (es)
SI (2)SI2508521T2 (es)
TW (2)TWI348468B (es)
UA (2)UA91401C2 (es)
UY (2)UY28559A1 (es)
WO (1)WO2005037824A2 (es)
ZA (1)ZA200602234B (es)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
CA2375259C (en)1999-06-212009-04-28Boehringer Ingelheim Pharma KgBicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
US7019012B2 (en)*2000-12-202006-03-28Boehringer Ingelheim International Pharma Gmbh & Co. KgQuinazoline derivatives and pharmaceutical compositions containing them
DE10221018A1 (de)*2002-05-112003-11-27Boehringer Ingelheim PharmaVerwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
US20050043233A1 (en)*2003-04-292005-02-24Boehringer Ingelheim International GmbhCombinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
DE10349113A1 (de)*2003-10-172005-05-12Boehringer Ingelheim PharmaVerfahren zur Herstellung von Aminocrotonylverbindungen
KR100832594B1 (ko)*2005-11-082008-05-27한미약품 주식회사다중저해제로서의 퀴나졸린 유도체 및 이의 제조방법
ES2412879T3 (es)*2005-11-112013-07-12Boehringer Ingelheim International GmbhTratamiento combinado del cáncer que comprende inhibidores de EGFR/HER2
WO2007054550A1 (en)*2005-11-112007-05-18Boehringer Ingelheim International GmbhQuinazoline derivatives for the treatment of cancer diseases
SI1981863T1 (sl)*2006-01-262013-01-31Boehringer Ingelheim International GmbhPostopek za pripravo aminokrotonilamino-substituiranih kinazolinskih derivatov
ATE552835T1 (de)2006-09-182012-04-15Boehringer Ingelheim IntVerfahren zur behandlung von tumoren mit egfr- mutationen
PE20100252A1 (es)*2008-06-062010-04-12Boehringer Ingelheim IntNuevas formulaciones farmaceuticas solidas que comprenden dimaleato de 4-[(3-cloro-4-fluorofenil) amino]-6-{[4-(n,n-dimetilamino)-1-oxo-2-buten-1-il] amino}-7-((s)-tetrahidrofuran-3-iloxi)-quinazolina
WO2010081817A1 (en)2009-01-142010-07-22Boehringer Ingelheim International GmbhMethod for treating colorectal cancer
AU2010221818A1 (en)2009-03-112011-10-06Auckland Uniservices LimitedProdrug forms of kinase inhibitors and their use in therapy
EP2429520A1 (en)2009-05-142012-03-21Boehringer Ingelheim International GmbHNew combination therapy in treatment of oncological and fibrotic diseases
CA2804190A1 (en)*2009-07-022011-01-06Newgen Therapeutics, Inc.Phosphorus containing quinazoline compounds and methods of use
DK2451445T3 (da)2009-07-062019-06-24Boehringer Ingelheim IntFremgangsmåde til at tørre bibw2992, dets salte og faste farmaceutiske formuleringer omfattende denne aktive ingrediens
EP2509592A1 (en)2009-12-072012-10-17Boehringer Ingelheim International GmbHBibw 2992 for use in the treatment of triple negative breast cancer
US20120107304A1 (en)2010-04-272012-05-03Boehringer Ingelheim International GmbhCombination therapy in treatment of oncological and fibrotic diseases
SI2608792T1 (en)2010-08-262018-02-28Boehringer Ingelheim International Gmbh Methods for the administration of an EGFR inhibitor
KR20130105675A (ko)2010-11-252013-09-25라티오팜 게엠베하아파티닙의 신규 염 및 다형
SG10201601711SA (en)2011-03-042016-04-28Newgen Therapeutics IncAlkyne Substituted Quinazoline Compound And Methods Of Use
CN102731485B (zh)*2011-04-022016-06-15齐鲁制药有限公司4-(取代苯氨基)喹唑啉衍生物及其制备方法、药物组合物和用途
CN102918029B (zh)2011-05-172015-06-17江苏康缘药业股份有限公司4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
US8828391B2 (en)2011-05-172014-09-09Boehringer Ingelheim International GmbhMethod for EGFR directed combination treatment of non-small cell lung cancer
CN102838590B (zh)*2011-06-212014-07-09苏州迈泰生物技术有限公司氨基喹唑啉衍生物及其在制备抗恶性肿瘤药物中的用途
US20170079444A1 (en)*2011-09-222017-03-23Future Foam, Inc.Enhanced washable mattress topper
WO2013052157A1 (en)2011-10-062013-04-11Ratiopharm GmbhCrystalline forms of afatinib di-maleate
CN103073539B (zh)*2011-10-262016-05-11齐鲁制药有限公司4-(取代苯氨基)喹唑啉衍生物及其制备方法、药物组合物和用途
EP2875020B1 (en)2012-07-192017-09-06Boehringer Ingelheim International GmbHProcess for the preparation of a fumaric acid salt of 9-[4-(3-chloro-2-fluoro-phenylamino)-7-methoxy- chinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undecan-5-one
EP2951171A1 (en)2013-02-012015-12-09Boehringer Ingelheim International GmbHRadiolabeled quinazoline derivatives
CN103254156B (zh)*2013-05-102015-08-26苏州明锐医药科技有限公司阿法替尼中间体的制备方法
WO2014180271A1 (zh)*2013-05-102014-11-13苏州明锐医药科技有限公司阿法替尼及其中间体的制备方法
CN103242303B (zh)*2013-05-162015-03-25苏州明锐医药科技有限公司阿法替尼的制备方法
CN103288808B (zh)*2013-05-162015-11-11苏州明锐医药科技有限公司一种阿法替尼的制备方法
CN104540820B (zh)*2013-07-162016-12-21杭州普晒医药科技有限公司阿法替尼酸加成盐及其晶型、其制备方法及药物组合物
CN104513229A (zh)*2013-09-282015-04-15正大天晴药业集团股份有限公司喹唑啉衍生物及其制备方法
CN104710413B (zh)*2013-12-162019-05-03江苏豪森药业集团有限公司二马来酸阿法替尼的制备方法
CN104744445A (zh)*2013-12-302015-07-01广东东阳光药业有限公司一种酪氨酸激酶抑制剂的晶型
US9242965B2 (en)2013-12-312016-01-26Boehringer Ingelheim International GmbhProcess for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
EA031059B1 (ru)*2014-01-022018-11-30Тева Фармасьютикалз Интернэшнл ГмбхКристаллическая форма альфа дималеата афатиниба
CN104803992A (zh)*2014-01-252015-07-29广东东阳光药业有限公司阿法替尼盐的晶型
WO2016001844A1 (en)*2014-06-302016-01-07Sun Pharmaceutical Industries LimitedAmorphous form of afatinib dimaleate
CN105315263B (zh)*2014-07-302018-11-27正大天晴药业集团股份有限公司阿法替尼中间体的合成方法
WO2016027243A1 (en)*2014-08-212016-02-25Dr. Reddy’S Laboratories LimitedNovel solid state forms of afatinib dimaleate
EP3201190A4 (en)*2014-10-012018-03-14Sun Pharmaceutical Industries LtdCrystalline form of afatinib dimaleate
CN105534920B (zh)*2014-10-292020-07-10江苏豪森药业集团有限公司一种药物组合物及其制备方法
CN104402872B (zh)*2014-11-142016-08-24广东东阳光药业有限公司一种结晶除杂方法
CN104447713B (zh)*2014-11-182019-03-29江苏奥赛康药业股份有限公司阿法替尼化合物的制备方法
EP3023421A1 (en)2014-11-212016-05-25Sandoz AgCrystalline forms of afatinib dimaleate
CN104529800B (zh)*2014-12-082017-01-25重庆威鹏药业有限公司反式‑4‑二甲基氨基巴豆酸及盐的制备方法
CN105801567A (zh)*2014-12-312016-07-27徐州万邦金桥制药有限公司一种双马来酸阿法替尼的纯化方法
CN105801568B (zh)*2015-01-152019-07-30杭州普晒医药科技有限公司阿法替尼一马来酸盐晶型及其制备方法和药物组合物
JP6704422B2 (ja)2015-03-202020-06-03チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッドChia Tai Tianqing Pharmaceutical Group Co., Ltd.キナゾリン誘導体の塩およびその製造方法
KR20180003542A (ko)*2015-04-172018-01-09헤테로 랩스 리미티드아파티닙과 그 염의 다형체 및 퀴나졸린일 유도체 제조 방법
CN105859641B (zh)*2015-05-052018-11-16杭州华东医药集团新药研究院有限公司喹唑啉巴豆基化合物二马来酸盐的晶体及其制备方法和用途
CN104892584B (zh)*2015-05-272018-03-23重庆泰濠制药有限公司一种阿法替尼双马来酸盐无定型态及其制备方法、制剂
AU2016276426B2 (en)*2015-06-122019-12-05Fresenius Kabi Oncology Ltd.Polymorphic forms of Afatinib free base and Afatinib dimaleate
CN104926800A (zh)*2015-06-262015-09-23河北神威药业有限公司一种阿法替尼二马来酸盐的结晶形式及其制备方法
CN105175331B (zh)*2015-08-142019-04-26江苏苏中药业集团股份有限公司一种egfr类分子靶向抗肿瘤药物的制备方法
KR20180066039A (ko)2015-08-212018-06-18프레세니어스 카비 온콜로지 리미티드아파티닙을 포함하는 약학적 조성물
WO2017093789A1 (en)*2015-12-032017-06-08Mylan Laboratories Ltd.Polymorphic forms of afatinib dimaleate
CN106831733B (zh)*2015-12-072021-05-11海南先声药业有限公司阿法替尼顺式异构体的制备方法与应用
CN106866641A (zh)*2015-12-112017-06-20河北神威药业有限公司一种阿法替尼的精制方法
CN106916147A (zh)*2015-12-252017-07-04中美华世通生物医药科技（武汉）有限公司化合物及其制备方法和用途
EP3395811B1 (en)2015-12-252020-05-13Xuanzhu Pharma Co., Ltd.Crystals of quinazoline derivative and preparation method therefor
CN105669658B (zh)*2016-04-052018-06-29北京民康百草医药科技有限公司一种阿法替尼的精制方法
CN107488153B (zh)*2016-06-102020-06-23山东新时代药业有限公司一种阿法替尼中间体化合物
CN107488171B (zh)*2016-06-102020-08-28山东新时代药业有限公司一种阿法替尼制备方法
CN107488172B (zh)*2016-06-102020-06-12山东新时代药业有限公司一种阿法替尼的制备方法
CN107488194B (zh)*2016-06-102021-07-30山东新时代药业有限公司一种阿法替尼中间体及其制备方法
CN106243092B (zh)*2016-07-282019-02-15南京臣功制药股份有限公司一种高选择性制备马来酸阿法替尼的方法
TWI782931B (zh)2016-11-172022-11-11美國德州系統大學評議委員會具有對抗帶有egfr或her2外顯子20突變之癌細胞之抗腫瘤活性的化合物
TWI808958B (zh)2017-01-252023-07-21美商特普醫葯公司涉及二芳基巨環化合物之組合療法
CA3057716A1 (en)2017-04-062018-10-11Johnson Matthey Public Limited CompanyNovel forms of afatinib dimaleate
CN108358900A (zh)*2018-03-302018-08-03东北制药集团股份有限公司一种阿法替尼及其马来酸盐的制备方法
KR20190141607A (ko)2018-06-142019-12-24주식회사 에이티파머알로페론을 포함하는 췌장암 치료용 조성물 및 치료 보조제
KR102257913B1 (ko)2018-07-172021-05-28주식회사 에이티파머알로페론을 포함하는 폐섬유증 치료용 조성물
CN109824657A (zh)*2019-03-262019-05-31石药集团中奇制药技术（石家庄）有限公司一种二马来酸阿法替尼新晶型及其制备方法和应用
CN110563710B (zh)*2019-09-212020-05-19广东安诺药业股份有限公司一种马来酸阿法替尼的制备方法
CN110590754A (zh)*2019-09-212019-12-20广东安诺药业股份有限公司一种马来酸阿法替尼中间体的制备方法
CN113121512B (zh)*2019-12-302022-11-04江苏晶立信医药科技有限公司一种喹唑啉基丁烯酰胺类化合物的制备方法
KR20210106158A (ko)2020-02-202021-08-30서울대학교산학협력단알로페론을 포함하는 항암 치료 보조제
KR20210106157A (ko)2020-02-202021-08-30서울대학교산학협력단알로페론을 포함하는 난소암 치료용 조성물 및 치료 보조제
CN114315808A (zh)*2020-10-102022-04-12西安新通药物研究有限公司一种高收率马来酸阿法替尼的制备方法

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
GB8618846D0 (en)1986-08-011986-09-10Smithkline Beckman CorpChemical process
JPS6442472A (en)1987-08-101989-02-14Kanebo LtdQuinazoline derivative, production thereof and brain function disorder improving agent containing said derivative as active ingredient
GB9005014D0 (en)*1990-03-061990-05-02Janssen Pharmaceutica NvN.(4.piperidinyl)(dihydrobenzofuran or dihydro.2h.benzopyran)carboxamide derivatives
RU2043352C1 (ru)*1991-07-011995-09-10Пермский фармацевтический институт2-пропил-3- (5-нитрофурфулиден)амино- 4(3н)-хиназолинон, проявляющий противостафилококковую и анальгетическую активность
GB9300059D0 (en)1992-01-201993-03-03Zeneca LtdQuinazoline derivatives
GB9401182D0 (en)1994-01-211994-03-16Inst Of Cancer The ResearchAntibodies to EGF receptor and their antitumour effect
ES2161290T3 (es)1995-03-302001-12-01PfizerDerivados de quinazolina.
GB9508538D0 (en)1995-04-271995-06-14Zeneca LtdQuinazoline derivatives
DE69619114T2 (de)1995-07-062002-10-02Novartis Ag, BaselPyrolopyrimidine und verfahren zu ihrer herstellung
CN100503580C (zh)1996-04-122009-06-24沃尼尔·朗伯公司酪氨酸激酶的不可逆抑制剂
UA73073C2 (uk)1997-04-032005-06-15Уайт Холдінгз КорпорейшнЗаміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
ZA986732B (en)1997-07-291999-02-02Warner Lambert CoIrreversible inhibitiors of tyrosine kinases
ZA986729B (en)1997-07-291999-02-02Warner Lambert CoIrreversible inhibitors of tyrosine kinases
TW436485B (en)1997-08-012001-05-28American Cyanamid CoSubstituted quinazoline derivatives
GB9800569D0 (en)1998-01-121998-03-11Glaxo Group LtdHeterocyclic compounds
US6297258B1 (en)*1998-09-292001-10-02American Cyanamid CompanySubstituted 3-cyanoquinolines
US6262088B1 (en)1998-11-192001-07-17Berlex Laboratories, Inc.Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants
DE19911366A1 (de)1999-03-152000-09-21Boehringer Ingelheim PharmaBicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
KR20020068261A (ko)*1999-02-272002-08-27베링거 잉겔하임 파르마 카게티로신 키나제에 의해 매개되는 신호 변환에 대한 억제효과를 갖는 4-아미노-퀴나졸린 및 퀴놀린 유도체
DE19911509A1 (de)1999-03-152000-09-21Boehringer Ingelheim PharmaBicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
CA2375259C (en)1999-06-212009-04-28Boehringer Ingelheim Pharma KgBicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
US6627634B2 (en)*2000-04-082003-09-30Boehringer Ingelheim Pharma KgBicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
US20030158196A1 (en)*2002-02-162003-08-21Boehringer Ingelheim Pharma Gmbh Co. KgPharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors
DE10063435A1 (de)*2000-12-202002-07-04Boehringer Ingelheim PharmaChinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US7019012B2 (en)*2000-12-202006-03-28Boehringer Ingelheim International Pharma Gmbh & Co. KgQuinazoline derivatives and pharmaceutical compositions containing them
DE10204462A1 (de)*2002-02-052003-08-07Boehringer Ingelheim PharmaVerwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
DE10221018A1 (de)*2002-05-112003-11-27Boehringer Ingelheim PharmaVerwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
US20030225079A1 (en)*2002-05-112003-12-04Boehringer Ingelheim Pharma Gmbh & Co. KgUse of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy
PE20040945A1 (es)*2003-02-052004-12-14Warner Lambert CoPreparacion de quinazolinas substituidas
US20050043233A1 (en)2003-04-292005-02-24Boehringer Ingelheim International GmbhCombinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
DE10349113A1 (de)2003-10-172005-05-12Boehringer Ingelheim PharmaVerfahren zur Herstellung von Aminocrotonylverbindungen
US20060058311A1 (en)2004-08-142006-03-16Boehringer Ingelheim International GmbhCombinations for the treatment of diseases involving cell proliferation
WO2007054550A1 (en)*2005-11-112007-05-18Boehringer Ingelheim International GmbhQuinazoline derivatives for the treatment of cancer diseases
ES2412879T3 (es)*2005-11-112013-07-12Boehringer Ingelheim International GmbhTratamiento combinado del cáncer que comprende inhibidores de EGFR/HER2
SI1981863T1 (sl)*2006-01-262013-01-31Boehringer Ingelheim International GmbhPostopek za pripravo aminokrotonilamino-substituiranih kinazolinskih derivatov
ATE552835T1 (de)2006-09-182012-04-15Boehringer Ingelheim IntVerfahren zur behandlung von tumoren mit egfr- mutationen
US8022216B2 (en)2007-10-172011-09-20Wyeth LlcMaleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
PE20100252A1 (es)*2008-06-062010-04-12Boehringer Ingelheim IntNuevas formulaciones farmaceuticas solidas que comprenden dimaleato de 4-[(3-cloro-4-fluorofenil) amino]-6-{[4-(n,n-dimetilamino)-1-oxo-2-buten-1-il] amino}-7-((s)-tetrahidrofuran-3-iloxi)-quinazolina
WO2010081817A1 (en)2009-01-142010-07-22Boehringer Ingelheim International GmbhMethod for treating colorectal cancer
DK2451445T3 (da)*2009-07-062019-06-24Boehringer Ingelheim IntFremgangsmåde til at tørre bibw2992, dets salte og faste farmaceutiske formuleringer omfattende denne aktive ingrediens
EP2509592A1 (en)2009-12-072012-10-17Boehringer Ingelheim International GmbHBibw 2992 for use in the treatment of triple negative breast cancer
KR20130105675A (ko)2010-11-252013-09-25라티오팜 게엠베하아파티닙의 신규 염 및 다형
WO2013052157A1 (en)2011-10-062013-04-11Ratiopharm GmbhCrystalline forms of afatinib di-maleate
CN104540820B (zh)2013-07-162016-12-21杭州普晒医药科技有限公司阿法替尼酸加成盐及其晶型、其制备方法及药物组合物
WO2016027243A1 (en)2014-08-212016-02-25Dr. Reddy’S Laboratories LimitedNovel solid state forms of afatinib dimaleate
CN104892584B (zh)2015-05-272018-03-23重庆泰濠制药有限公司一种阿法替尼双马来酸盐无定型态及其制备方法、制剂
CN104926800A (zh)2015-06-262015-09-23河北神威药业有限公司一种阿法替尼二马来酸盐的结晶形式及其制备方法

Also Published As

Publication numberPublication date
EP2508521A3 (de)2013-01-23
EP2508521B1 (de)2015-12-30
EA016624B1 (ru)2012-06-29
EP2508521A2 (de)2012-10-10
SI2508521T1 (sl)2016-03-31
NZ583049A (en)2011-08-26
IL216249A (en)2015-05-31
RS60563B1 (sr)2020-08-31
IL216249A0 (en)2011-12-29
ES2563211T3 (es)2016-03-11
RS20130524A3 (en)2015-08-31
BR122013033343B1 (pt)2020-10-13
MX338920B (es)2016-05-06
CY1114866T1 (el)2016-12-14
MEP50808A (en)2011-02-10
US8426586B2 (en)2013-04-23
EP1678165B1 (de)2013-09-25
PT2508521E (pt)2016-03-31
HRP20160246T4 (hr)2022-11-11
AU2011201171B2 (en)2012-02-09
TW200526644A (en)2005-08-16
CA2541928A1 (en)2005-04-28
JP2007510624A (ja)2007-04-26
PL2508521T3 (pl)2016-06-30
UY28559A1 (es)2005-05-31
EP1678165A2 (de)2006-07-12
TWI373470B (en)2012-10-01
NO20130663L (no)2006-05-15
JP4594317B2 (ja)2010-12-08
KR20060120121A (ko)2006-11-24
IL174951A0 (en)2006-08-20
DK2508521T4 (da)2022-10-03
MY155425A (en)2015-10-15
DE10349113A1 (de)2005-05-12
RS20060260A (en)2008-06-05
UA91401C2 (en)2010-07-26
ME00341B (me)2011-05-10
US20070027170A1 (en)2007-02-01
WO2005037824A2 (de)2005-04-28
MY149921A (en)2013-10-31
BRPI0415424B1 (pt)2019-01-22
SI1678165T1 (sl)2013-12-31
HRP20160246T1 (hr)2016-04-08
ES2440466T3 (es)2014-01-29
CN1867564A (zh)2006-11-22
NZ547154A (en)2010-02-26
HUE028254T2 (en)2016-12-28
CN101402631A (zh)2009-04-08
JP5264830B2 (ja)2013-08-14
BRPI0415424A (pt)2006-12-05
TW201118086A (en)2011-06-01
BRPI0415424B8 (pt)2021-05-25
SI2508521T2 (sl)2022-11-30
DK1678165T3 (da)2013-12-09
NO335103B1 (no)2014-09-15
JP2010202668A (ja)2010-09-16
AU2004281938B2 (en)2011-04-14
BR122013033343B8 (pt)2021-05-25
AU2004281938A1 (en)2005-04-28
UY35979A (es)2016-09-30
AU2011201171A1 (en)2011-04-07
PT1678165E (pt)2013-11-07
SG139743A1 (en)2008-02-29
TWI348468B (en)2011-09-11
PE20100267A1 (es)2010-04-21
HRP20131214T1 (hr)2014-01-31
KR101282812B1 (ko)2013-07-05
KR101180752B1 (ko)2012-09-10
MXPA06004076A (es)2006-06-27
ZA200602234B (en)2007-09-26
EA200600604A1 (ru)2006-10-27
PL2508521T5 (pl)2023-03-27
WO2005037824A3 (de)2005-07-21
NO333971B1 (no)2013-11-04
AR046118A1 (es)2005-11-23
HK1095817A1 (en)2007-05-18
UA91006C2 (ru)2010-06-25
IL174951A (en)2012-03-29
US20050085495A1 (en)2005-04-21
CA2541928C (en)2012-12-11
NO20062181L (no)2006-05-15
RS53398B (en)2014-10-31
CA2759063C (en)2012-04-17
DK2508521T3 (en)2016-03-29
KR20120037987A (ko)2012-04-20
CY1117279T1 (el)2017-04-26
ECSP066509A (es)2006-10-10
CN1867564B (zh)2011-06-08
RS20130524A2 (en)2014-06-30
PL1678165T3 (pl)2014-03-31
EP2508521B2 (de)2022-09-07
ES2563211T5 (es)2022-12-27
CA2759063A1 (en)2005-04-28

Similar Documents

PublicationPublication DateTitle
PE20050965A1 (es)Procedimiento para la preparacion de compuestos de aminocrotonilo
PE20060921A1 (es)Procedimiento para preparar 8-(3-amino-piperidin-1-il)-xantinas quirales
EA201101583A1 (ru)Ингибиторы pi3 киназы или mtor
ATE517882T1 (de)Chinolinderivate
EA201390579A1 (ru)Производные хиназолин-4(3h)-она, используемые как ингибиторы pi3-киназы
NO20063693L (no)Forbindelse og metode for anvendelse
EA200870302A1 (ru)1,3-диоксанкарбоновые кислоты
EP2682387A3 (en)C7-fluoro substituted tetracycline compounds
CU20100062A7 (es)Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteínas quinasas b
EA201171415A1 (ru)Ингибиторы белков семейства iap
MY155836A (en)Thienopyridone derivatives as amp-activated protein kinase (ampk) activators
DOP2006000169A (es)Inhibidores espiropiperidina de beta-secretasa para el tratamiento de la enfermedad de alzheimer
EA201201343A1 (ru)Производные 4-аминопиримидина и их действующее вещество как антагонисты аденозинового рецептора а
EA201001017A1 (ru)3h-[1,2,3]триазоло[4,5-d]пиримидиновые соединения, их применение в качестве ингибиторов киназы mtor и киназы pi3 и их синтезы
EA201200260A1 (ru)Гетероциклические гидразоны и их применение для лечения рака и воспаления
NI201000145A (es)DERIVADOS DE IMIDAZO - [1, 2-b] - PIRIDAZINA PARA EL TRATAMIENTO DE ENFERMEDAD MEDIADA POR CINASA DE TIROSINA C-MET.
EA201101672A1 (ru)Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина
EA201200763A1 (ru)Замещенные производные карбамоилметиламиноуксусной кислоты в качестве новых ингибиторов nep
EA201291348A1 (ru)Активаторы растворимой гуанилатциклазы
NO20080865L (no)Spirokromanonderivater som acetyl-koenzym-A-karboksylase(ACC)inhibitorer
CL2008002330A1 (es)Compuestos derivados de alcoholes de 1-fenil-2-piridinilalquilo, inhibidores de la fosfodiesterasa 4 (pde4); proceso de preparacion de dichos compuestos; composiciones farmaceuticas que los contienen; y su uso para preparar medicamentos utiles en la prevencion o tratamiento de asma, bronquitis cronica y epoc.
EA201270492A1 (ru)Соединения для лечения дислипидемии и связанных с ней заболеваний
EA200802288A1 (ru)Замещенные имидазолы, композиция на их основе, способ профилактики или лечения нежелательного тромбообразования с их помощью и способ ингибирования коагуляции образцов крови
EA201300250A1 (ru)Оксадиазольные ингибиторы продуцирования лейкотриена
UA103617C2 (ru)Производные тиенопиридона как активаторы амр-активированной протеинкиназы (амрк)

Legal Events

DateCodeTitleDescription
FCRefusal
FGGrant, registration
[8]ページ先頭
©2009-2025 Movatter.jp